Ostalo

UNDERESTIMATED FREQUENCY OF RESISTANT HYPERTENSION IN PREDIALYSIS NONDIABETIC PATIENTS

INGRID PRKAčIN ; Klinička bolnica Merkur, Medicinski fakultet Sveučilišta u Zagrebu, Klinika za unutarnje bolesti, Zagreb, Hrvatska
DIANA BALENOVIć ; Opća bolnica Sisak, Odjel za unutarnje bolesti, Sisak, Hrvatska
PETRA PRKAčIN ; Opća bolnica Sisak, Odjel za unutarnje bolesti, Sisak, Hrvatska
ANDRIJA JURINA ; Klinička bolnica Merkur, Medicinski fakultet Sveučilišta u Zagrebu, Klinika za unutarnje bolesti, Zagreb, Hrvatska
LOVRO ŠANTEK ; Klinička bolnica Merkur, Medicinski fakultet Sveučilišta u Zagrebu, Klinika za unutarnje bolesti, Zagreb, Hrvatska
DINO KASUMOVIć ; Klinička bolnica Merkur, Medicinski fakultet Sveučilišta u Zagrebu, Klinika za unutarnje bolesti, Zagreb, Hrvatska
GORDANA CAVRIć ; Klinička bolnica Merkur, Medicinski fakultet Sveučilišta u Zagrebu, Klinika za unutarnje bolesti, Zagreb, Hrvatska
TOMISLAV BULUM ; Klinička bolnica Merkur, Medicinski fakultet Sveučilišta u Zagrebu, Klinika za unutarnje bolesti, Zagreb, Hrvatska

Sažetak

The real prevalence of resistant hypertension (RH) is unknown. Studies suggest that it affects 10%-15% of patients treated for hypertension by primary care physicians. RH is deined as blood pressure (BP) remaining above the goal despite the use of optimal doses of 3 or more medicines of different classes (including a diuretic). It means BP >140/90 mm Hg for the general population and >130/80 mm Hg for patients with diabetes or kidney disease. Prior to diagnosing a patient as having RH, it is important to document medication compliance and exclude white-coat hypertension, inaccurate BP measurement, and secondary causes.
The role of aldosterone in RH has gained increasing recognition. There is strong evidence for the use of spironolactone as a highly effective antihypertensive agent. Aldosterone plays a signiicant role in RH pathogenesis, primarily due to its vasoconstrictive effects and the possibility of altering vascular compliance. In RH, there is a high prevalence of cardiac and extra-cardiac target organ damage. It is known that BP control in chronic kidney disease is the key factor for reducing cardiovascular risk and renal disease progression. The objective of the study was to evaluate the prevalence of RH in predialysis nondiabetic (CKD stage I-IV)
patients.

Ključne riječi

resistant hypertension; predialysis nondiabetic patients

Hrčak ID:

97575

URI

https://hrcak.srce.hr/97575

Datum izdavanja:

14.2.2013.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.408 *